H.C. Wainwright Reiterates a Buy on BridgeBio Pharma (BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the Best Performing Long Term Stocks According to Analysts. On September 15, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) with a price target of $70.

The analyst noted that his positive sentiment of the company is based on the company’s lead drug candidate Encaleret, which targets autosomal dominant hypocalcemia type 1 (ADH1). ADH1 is a rare condition with high unmet medical needs and often goes undiagnosed. He highlighted that Encaleret works differently from conventional treatments and acts as a negative allosteric modulator of the calcium-sensing receptor. This mechanism directly addresses the root cause of ADH1, which current therapies do not fully manage.

Moreover, the drug has shown strong results in a Phase 2 trial. Over 42 months, it helped normalize patients’ blood calcium, parathyroid hormone, and urine calcium levels. Importantly, Encaleret demonstrated a durable effect and a good safety profile over this long-term study.

In the United States alone there are around 12,000 patients affected by ADH1, presenting a sizable market opportunity for BridgeBio Pharma, Inc. (NASDAQ:BBIO).

BridgeBio Pharma, Inc. (NASDAQ:BBIO) discovers and develops medicines for genetic diseases. Its drug pipeline includes treatments for amyloidosis, achondroplasia, hypocalcemia, and muscular dystrophy.

While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.